RUNX2 Phase Separation Mediates Long-Range Regulation Between Osteoporosis-Susceptibility Variant and XCR1 to Promote...

Area of Science:

• Genetics
• Molecular Biology
• Bone Biology

Background:

• Genome-wide association studies (GWASs) have identified numerous osteoporosis-associated loci.
• The precise genetic regulatory mechanisms and potential therapeutic targets remain underexplored.

Purpose of the Study:

• To elucidate the functional role of a GWAS-identified intergenic single nucleotide polymorphism (SNP) in osteoporosis.
• To investigate the underlying molecular mechanisms involving gene regulation and chromatin interactions.
• To identify novel therapeutic targets for osteoporosis.

Main Methods:

• Analysis of a GWAS intergenic SNP (rs4683184) as a potential enhancer.
• Investigation of transcription factor RUNX2 binding affinity and its role in phase separation.
• Assessing long-range chromatin interactions between the enhancer and the XCR1 gene.
• Evaluating the effect of XCR1 expression on osteoblast differentiation.
• Utilizing bone-targeting adeno-associated virus (AAV) in osteoporosis mouse models.

Main Results:

• The GWAS SNP rs4683184 functions as an enhancer, modulating RUNX2 transcription factor binding.
• RUNX2-mediated phase separation facilitates long-range chromatin interaction between the enhancer and the XCR1 gene.
• Altered XCR1 expression impacts osteoblast differentiation.
• Bone-targeting AAV delivery of Xcr1 enhances bone formation in osteoporosis models.
• XCR1 is identified as a novel susceptibility gene for osteoporosis.

Conclusions:

• This study establishes a novel regulatory mechanism linking a non-coding SNP to complex disease susceptibility via phase separation and long-range chromatin interactions.
• XCR1 emerges as a potential therapeutic target for osteoporosis, with implications for drug development and translational research.